ScanCLAD is an investigator initiated, controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of Chronic Lung Allograft Dysfunction after lung transplantation (EudraCT number 2015-004137-27)
The study started in the end of 2016, and is planned to continue through 2022 for follow up of all patients. It is carried out as a collaboration between five University Hospitals in Scandinavia:
- Sahlgrenska University Hospital in Gothenburg, Sweden
- Skåne University Hospital in Lund, Sweden
- Rigshospitalet in Copenhagen, Denmark
- Oslo University Hospital in Oslo, Norway
- Helsinki University Hospital in Helsinki, Finland
This home page has primarily been set up as a tool for communication between the people involved in conducting this study.
